Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChina Pacific Regulatory News (CPIC)

Share Price Information for China Pacific (CPIC)

Share Price is delayed by 15 minutes
Get Live Data
26.60    0.00 (0.00%)
Bid:
22.60
Ask:
23.60
Spread: 1.00 (4.425%)
Market Cap: $51.18b
CPIC Live PriceLast checked at - London Stock Exchange

Intraday China Pacific Share Chart

  • This share is an international stock.

Stabilisation Notice

3 Jul 2020 10:00

RNS Number : 9752R
UBS AG London Branch
03 July 2020
Β 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

Β 

3 July 2020

Β 

China Pacific Insurance (Group) Co., Ltd.

Post-Stabilisation NoticeΒ 

Β 

Further to the pre-stabilisation period announcement dated 16 June 2020, UBS AG London Branch (Contact: Francois-Olivier Mercier, Syndicate Desk: +44 20756 87504) hereby gives notice that stabilisation (within the meaning of Commission Delegated Regulation (EU) 2016/1052 supplementing the Market Abuse Regulation (EU) 596/2014) in relation to the offer of the following securities had been undertaken by it or any of its affiliates in accordance with the rules of the Financial Conduct Authority.

Β 

The securities:

Issuer:

China Pacific Insurance (Group) Co., Ltd.

Securities:

Global Depositary Receipts ("GDRs") each representing 5 A shares of the Company

ISIN:

US16951T1198

Offering size:

Institutional Offering: 102,873,300 GDRs (excluding the over-allotment option)

Market:

London Stock Exchange plc, Shanghai-London Stock Connect segment

Ticker:

CPIC

Description:

Initial Public Offering of GDRs

Offer price:

US$17.60 per GDR

Associated securities:

There are no associated instruments that are subject to stabilisation

Β 

For each of the dates during which stabilisation transactions were carried out, the price range was as follows:

Β 

Trade Date

Lowest price (US$)

Highest price (US$)

Trading Venue

17/06/2020

17.60

17.60

LSE

29/06/2020

17.60

17.60

LSE

Β 

On 3 July 2020, UBS AG London Branch, as Stabilisation Manager, exercised the overallotment option granted by China Pacific Insurance (Group) Co., Ltd. in respect of 8,794,991 GDRs of the Company (the "Option GDRs") at the offer price of US$17.60 per Option GDR.

Β 

Following the exercise of the over-allotment option, the stabilisation period is hereby terminated as of the date hereof.

Important legal information

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada, Japan, South Africa or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement is not an offer to sell, or solicitation of an offer to buy, acquire or subscribe for any securities to any person in the United States (including its territories and possessions, any state of the United States and the District of Columbia) or in any other jurisdiction in which such offer or solicitation would be unlawful. The GDRs have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any State or other jurisdiction of the United States and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable state or local securities law. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements.

In any member state of the European Economic Area (the "EEA") (each, a "Relevant Member State"), this announcement and the Offering are only addressed to and directed at persons who are "qualified investors" ("Qualified Investors") within the meaning of the Regulation (EU) 2017/1129 (the "Prospectus Regulation").

In the United Kingdom, this announcement and any offer if made subsequently is only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth entities who fall within Article 49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as "relevant persons"). This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors and other persons who are permitted to subscribe for the GDRs described herein pursuant to an exemption from the Prospectus Regulation and other applicable legislation, and will only be engaged in with such persons.

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
STARJMRTMTAMMLM
Date   Source Headline
8th Jun 202612:30 pmRNSApproval of Director's Appointment Qualification
26th May 202611:05 amRNSAppointment of Vice President
20th May 202610:26 amRNSNotice of the 2025 Annual General Meeting
30th Apr 20269:50 amRNSDirector/PDMR Shareholding
28th Apr 202610:48 amRNSPublication of Summaries of Solvency Reports
28th Apr 202610:36 amRNS2026 First Quarter Report
22nd Apr 202610:35 amRNS2025 Sustainability Report
21st Apr 202611:10 amRNS2026 Q1 Results Presentation
14th Apr 202610:07 amRNSPDMR Shareholding
26th Mar 202612:32 pmRNSPublication of Annual Results Presentation
26th Mar 202612:22 pmRNSPublication of Summaries of Solvency Reports
26th Mar 202612:16 pmRNSCPIC 2025 Annual Report
18th Mar 20269:40 amRNSConvening of 2025 Annual Results Presentation
26th Jan 202611:16 amRNSApproval of Director's Appointment Qualification
19th Jan 20269:35 amRNSAnnouncement relating to Premium Income
23rd Dec 202512:55 pmRNSApproval of AoA and Dissolution of the BOS
23rd Dec 202512:55 pmRNSApproval of AoA and Dissolution of the BOS
16th Dec 20259:17 amRNSAnnouncement relating to Premium Income
9th Dec 202510:10 amRNSRelevant presentations on 2025 investor day
4th Dec 20259:58 amRNSApproval of Director's Appointment Qualification
27th Nov 20259:06 amRNSDirector Shareholding
21st Nov 20259:10 amRNSElection of Employee Director
13th Nov 20259:11 amRNSAnnouncement relating to Premium Income
30th Oct 202511:02 amRNSSummaries of the Quarterly Solvency Reports
30th Oct 20259:54 amRNS2025 Third Quarter Report
21st Oct 202510:41 amRNS2025 Q3 Results Presentation
16th Oct 202511:36 amRNSAnnouncement relating to Premium Income
19th Sep 20257:00 amRNSPublication of Offering Circular of Bonds
18th Sep 202510:51 amRNSAnnouncement relating to Premium Income
18th Sep 202510:43 amRNSCompletion of the Issue of Convertible Bonds
18th Sep 202510:40 amRNSNotice of Listing of Convertible Bonds
11th Sep 20257:00 amRNSProposed issue of Bonds under General Mandate
10th Sep 202512:24 pmRNSProposed issue of Convertible Bonds
29th Aug 202512:35 pmRNSAnnouncement on Poll Results for the EGM
28th Aug 20252:24 pmRNSResignation of Supervisor
28th Aug 20251:25 pmRNSPublication of Summaries of Solvency Reports
28th Aug 20251:24 pmRNSPublication of 2025 Interim Results Presentation
28th Aug 20251:17 pmRNS2025 Interim Report
21st Aug 202511:47 amRNSConvening of 2025 Interim Results Presentation
13th Aug 202510:50 amRNSAnnouncement relating to Premium Income
11th Aug 202511:21 amRNSNotice of EGM
30th Jul 20254:01 pmRNSAmendments to the AoA and dissolution of the BOS
15th Jul 202511:23 amRNSAnnouncement relating to Premium Income
24th Jun 202510:23 amRNSResignation of Director of the Board
13th Jun 202510:15 amRNSAnnouncement relating to Premium Income
11th Jun 202512:58 pmRNSPoll Results for the 2024 AGM
6th Jun 202510:48 amRNSApproval of Appointment Qualification
21st May 202511:19 amRNSNotice of the 2024 Annual General Meeting
14th May 202511:30 amRNSAnnouncement relating to Premium Income
12th May 202512:01 pmRNSAnnouncement relating to Change of Committee

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.